美国 豪洛捷 Hologic
Hologic公司于1986年由前任总裁和董事长S. David Ellenboger和首席技术总监Jay A. Stein创办，是一家致力于满足女性健康医疗，提供最先进的医学影像系统的公司。

　　Hologic公司自创办起，就一直致力于开发和提供日益发展的医学影像系统，以满足现代医学女性健康医疗的需要。它首先开发出最先进的放射学数字影像技术并应用于乳腺照像。当前Hologic公司的业务主要集中在骨质疏松检测系统、乳腺照像和乳腺活组织检测系统、数字化X线检测系统以及适用于骨科小型C型臂检测系统。

　　1987年，Hologic公司在骨密度检测方法中取得突破，是首家推出双能X线骨密度仪（DXA）的公司。目前Hologic公司还在不断开发、生产和销售X线骨密度仪和超声骨分析仪，以用于临床骨质疏松的预防和治疗。公司生产的是数字化放射检测系统（QDR）已在X线骨密度仪中得到应用，通过精确测量骨密度，大大提高了骨质疏松症的诊断水平，并能对包括骨质疏松在内的骨代谢疾病的治疗进行良好的监测。

　　Hologic公司正在继续努力以保证其在该领域的领先水平，最引人注目的是最近新研发生产的Discovery QDR系列骨密度仪和脊椎快速评价技术的应用。

　　Hologic公司生产的骨密度仪目前已遍布许多先进的医学院校、研究机构和骨质疏松领域里一些著名专家的实验室。在全球已有10000台在工作.

Hologic, Inc. (NASDAQ: HOLX) is a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems, and surgical products dedicated to serving the healthcare needs of women throughout the world.

Historically, Hologic developed, manufactured, and marketed products focused on mammography, breast care, and osteoporosis assessment. In 2007, we expanded our focus and now provide a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, mini C-arms for extremity imaging, and molecular diagnostic products including reagents for a variety of DNA and RNA analysis applications. We are proud of this achievement, and conscious of the responsibility that our leadership position brings with it. We believe that the health issues facing women today deserve and demand the singular dedication of a passionate company.

Our core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health.

Breast Health

"You have cancer. Fortunately, we caught it early."

Hologic's largest business is breast cancer diagnosis and treatment. Each year, more than one million women in the U.S. are diagnosed with breast cancer, while hundreds of thousands of them fall victim to this dreaded disease. One out of eight American women will get breast cancer in her lifetime. Fortunately when breast cancer is detected and treated in its earliest stages, the five-year survival rate is 98 percent.

In 2007, 92 percent of the mammography breast cancer screening systems sold in the United States were digital. The Hologic Selenia™ system is at the forefront of this wave, setting a standard for excellence in digital mammography.

We continue to introduce advances in imaging and interpretation, such as the first tungsten x-ray tube with a special silver filter that allows digital mammography images to be acquired at a lower radiation dose and shorter exposure times. We have integrated the R2™ computer-aided detection (CAD) into our SecurView™ diagnostic workstations, giving clinicians a sophisticated pattern recognition software tool to help find cancers at an early stage.

Hologic is helping imaging centers deliver a "high-tech, soft-touch" experience with the MammoPad® radiolucent breast cushion. The MammoPad cushion provides patient comfort, while aiding in breast positioning, compression, and tissue acquisition.

Each year in the U.S. there are more than 600,000 open surgical breast biopsies. An estimated 80 percent of results are negative. The cost, risk, and trauma of these surgeries are enormous. Less invasive alternatives can drive down healthcare costs, support clinical efficiency, and, most importantly, cause far less distress for patients. Just as we are at the forefront of driving better detection solutions, our goal is to lead the industry in developing innovative technologies that make less invasive and more effective intervention possible and preferred.

Our MultiCare® Platinum stereotactic prone biopsy table and StereoLoc® II and digital StereoLoc II breast biopsy systems are designed to facilitate highly precise, image-guided procedures under minimally invasive conditions. We offer a wide number of interventional breast biopsy solutions including ATEC® percutaneous, automatic vacuum assisted breast biopsy systems, Celero® and Eviva™ ancillary biopsy devices, and a full line of biopsy site markers designed to provide compassionate care for every woman facing a breast cancer diagnosis.

When a cancer diagnosis is confirmed and radiation treatment is required, our MammoSite® targeted radiation therapy gives women a less traumatic alternative to mastectomies and whole breast irradiation. Using MammoSite therapy, clinicians can deliver a site-specific radiation dose inside the breast, reducing exposure to surrounding healthy tissue and organs. Four-year analysis of the MammoSite radiation therapy system has found that breast cancer recurrence rates with the MammoSite system continue to be comparable to the rates reported with standard radiation therapy.